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Quality Improvement Intervention for
Reduction of Redundant Testing
Alan M. Ducatman, MD, MS1, Danyel H. Tacker, PhD2,
Barbara S. Ducatman, MD2, Dustin Long, PhD3, Peter L. Perrotta, MD2,
Hannah Lawther, MD4, Kelly Pennington, MD5, Owen Lander, MD6,
Mary Warden, MD7, Conard Failinger, MD8, Kevin Halbritter, MD7,
Ronald Pellegrino, MD7, Marney Treese, MD9, Jeffrey A. Stead, MD10,11,
Eric Glass, DO12, Lauren Cianciaruso, DO13, and Konrad C. Nau, MD14
Abstract
Laboratory data are critical to analyzing and improving clinical quality. In the setting of residual use of creatine kinase M and B
isoenzyme testing for myocardial infarction, we assessed disease outcomes of discordant creatine kinase M and B isoenzyme þ/
troponin I () test pairs in order to address anticipated clinician concerns about potential loss of case-finding sensitivity following
proposed discontinuation of routine creatine kinase and creatine kinase M and B isoenzyme testing. Time-sequenced interven-
tions were introduced. The main outcome was the percentage of cardiac marker studies performed within guidelines. Non-
guideline orders dominated at baseline. Creatine kinase M and B isoenzyme testing in 7496 order sets failed to detect additional
myocardial infarctions but was associated with 42 potentially preventable admissions/quarter. Interruptive computerized soft
stops improved guideline compliance from 32.3% to 58% (P < .001) in services not receiving peer leader intervention and to >80%
(P < .001) with peer leadership that featured dashboard feedback about test order performance. This successful experience was
recapitulated in interrupted time series within 2 additional services within facility 1 and then in 2 external hospitals (including a
critical access facility). Improvements have been sustained postintervention. Laboratory cost savings at the academic facility were
estimated to be US$635 000 per year. National collaborative data indicated that facility 1 improved its order patterns from
fourth to first quartile compared to peer norms and imply that nonguideline orders persist elsewhere. This example illustrates
how pathologists can provide leadership in assisting clinicians in changing laboratory ordering practices. We found that clinicians
respond to local laboratory data about their own test performance and that evidence suggesting harm is more compelling to
clinicians than evidence of cost savings. Our experience indicates that interventions done at an academic facility can be readily
instituted by private practitioners at external facilities. The intervention data also supplement existing literature that electronic
order interruptions are more successful when combined with modalities that rely on peer education combined with dashboard
feedback about laboratory order performance. The findings may have implications for the role of the pathology laboratory in the
ongoing pivot from quantity-based to value-based health care.
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Introduction
The clinical laboratory and its data play a critical role in quality
improvement, including the detection, discussion, and deter-
rence of low-value services. “Low-value” services are
described as services that fail to improve care, that waste
resources, and may instigate harm.1,2 Persistence of low-
value clinical orders can descend from unfamiliarity with best
practice such as established clinical guidelines,3 from complex-
ity of implementing change,3 from perceived patient prefer-
ences,4 and from awareness of guideline limitations or their
local applicability.5,6
In seeking to eliminate low-value laboratory services,
pathologists should recognize clinician perceptions of change
can be affected by several human cognitive biases in addition to
their expressed concerns about patient well-being. For exam-
ple, “optimism bias” assumes that current activities are
rational; “confirmation bias” selectively filters information
contrary to preconceived beliefs, while “loss aversion (status
quo)” bias defends established routines.7,8 “Commission bias”
is the normal tendency to perceive that poor outcomes are more
likely to originate from inaction (in this case not ordering a
redundant test), compared to action.1 However, even when
these normal human biases may contribute undesirable
momentum for low-value services, clinicians generally articu-
late resistance to change in the language of patient needs and
patient care. To deal with visible and less visible barriers to
improving clinical value, an established research need is iden-
tifying the best practice to influence clinicians to abandon low-
value orders.7,9 Despite a current national focus on this
need,7,10-13 empirical studies of clinicians abandoning low-
value tests are “few and far between.”9
Clinical teams featuring pathologists are positioned to pro-
vide timely data and to address literature gaps concerning how
best to achieve changes leading to high-value services. The
diagnosis of myocardial infarction (MI) is common, clinically
important, and features a defined clinical laboratory order set.
Since 2007, the consensus laboratory standard has been sensi-
tive cardiac troponin T or troponin I (cTnI). Compared to pre-
vious tests, cTnI tests have superior sensitivity and specificity
for detecting myocardial injury.14-18 Creatine kinase M and B
isoenzyme (CKMB) testing does have occasional uses and may
be needed on rare occasions to diagnose uncommon condi-
tions.19-21 We therefore agreed readily to retain these tests in
our laboratory compendium. Nevertheless, the legitimate need
to retain the test did not explain why routine CKMB orders
persisted well past 2007 in our region and beyond.22-24 We also
planned to determine whether there was a need to intervene,
without eliminating clinician-desired access to the CKMB
orders. An Emergency Medicine (EM) Department conducted
an evaluation of discrepant cases and found no value to the
CKMB, followed by successful removal of the CKMB testing
from the emergency department (ED) menu, with attendant
cost savings.23 A community hospital has also shown that a
suite of unneeded MI tests, including CKMB and myoglobin,
can be eliminated from the routine evaluation of MI, with
substantial cost savings.24 The individual contributions of edu-
cation and changes to computerized provider order entry
(CPOE) could not be analyzed in this successful intervention.
At about the same time as we undertook our intervention, a
successful academic intervention was completed and described
at another university; the authors pointed out the unmet need to
translate interventions from academic settings to external
partners.22
In preliminary discussions, clinician leaders expressed
anticipated reservations about the possible loss of CKMB
and CK in order sets, including missed or delayed diag-
noses, with emphasis on unique aspects of regional popula-
tions (“our patients are different”) and potential
consequences (missed diagnoses, harm to patients, law-
suits).1,5,6,25 We recognized that expressed patient-
centered concern for missed diagnoses can mask equally
powerful unconscious cognitive bias.26 As part of their
quality improvement mission, pathologists can and should
evaluate the reality of such concerns. We hypothesized that
local data demonstrating that we could safely drop redun-
dant care markers without missing MIs would address the
stated patient-centered concerns and would be equally
effective to address unexpressed human perceptual biases,
especially if change process was driven by teamwork with
committed peer leaders who provide “academic detailing”
to colleagues.3,27,28 We also planned to gauge the effec-
tiveness of individual steps within a multimodal interven-




Baseline laboratory orders for chest pain/rule-out MI (R/O MI)
data were evaluated retrospectively from May 2008 through
July 2012 at the academic facility and then January 2013
through March 2014 at 2 external facilities. Test order data
included inpatient and outpatient settings, EM, and Urgent
Care. Under an institutional review board (IRB) for quality
improvement projects, summary CPOEs were obtained from
the laboratory information system (Sunquest version 6.2, Sun-
quest Information Systems, Tucson, Arizona) using an ad hoc
report writer (Crystal Reports XI, SAP, Newtown Square,
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Pennsylvania) to extract cTnI, CKMB, and CK test orders with
results including the calculated MB index (MBI) (all combina-
tions including CKMB, hereafter abbreviated as CKMB). Also
extracted were ordering location, clinician, and date/time of
testing. The data warehouse of West Virginia University Clin-
ical Translational Science Institute provided service-level data
for dashboard reports and data for rural hospitals who partici-
pated in a shared data warehouse.
Data Analysis
Microsoft Excel (Version 2010, Redmond, Washington) and
JMP (SAS Institute Inc, Cary, North Carolina) were used for
data trending, classification, distribution analysis, graphing,
and dashboard reports. Creatine kinase-only orders (not con-
taining cTnI or CKMB) were omitted as not related to the MI
diagnosis. Orders were classified as “guideline” (cTnI-only
orders) or “nonguideline” (any other included combination).
Because diagnostic volume varied, results are presented as
percentage adherent or nonadherent to guidelines. Differences
in percentages across time and across groups were tested using
w2 tests of association. A sensitivity analysis used generalized
linear mixed effects models (GLIMMs) with linear splines,
assuming that the distribution of guideline orders followed a
binomial distribution and was correlated over time within
groups, in order to test whether the probability of having a
guideline order was different immediately before and after
staged intervention components or preintervention/postinter-
vention. Analyses used SAS/STAT software, version 9.4 of the
SAS System for Windows (# 2012 SAS Institute Inc, Cary,
North Carolina).
Discordant Test Sensitivity Data
We evaluated the frequency of test discordance for a baseline
quarter, seeking any negative cTnI (cTnI[]) result, paired
with positive CKMB (CKMBþ) findings. We obtained IRB
permission to review medical records containing the
CKMBþ/cTnI() discordant finding in the last baseline quar-
ter, retrieving the following data for summary presentation: (1)
whether patient was admitted; (2) whether MI was diagnosed at
the time or over the next 6 months; (3) other occurrences of
hospitalization, (4) subsequent nuclear cardiac stress testing
and cardiac catheterization, with results. Figure 1 provides the
decision tree (and results).
Electronic Changes to Laboratory Test Orders
The EM peer leader and hospital administration including the
chief medical information officer (CMIO) initially selected a
minimally interruptive “soft stop” that changed a default order
set that had included CKMB and CK. With this change, the order-
ing clinician now had to select these tests from a visible checklist,
adding an estimated 1 second to enter a nonguideline order. After
trial evaluation, the CMIO removed CKMB and CK tests from
R/O MI order sets while retaining them in the laboratory catalog
as a separate order requiring an estimated 15 to 30 seconds.
Intervention including Academic Detailing
Standards for Quality Improvement Reporting Excellence
(SQUIRE version 1.0)29 influenced the interrupted time series
design. Figure 2 provides intervention elements and time
sequence details of intervention, also illustrating the dates of
data collection. General education sessions (rounds) provided
R/O MI laboratory consensus standards15,30 during the initial
planning period and introduced impending changes to order
sets. The results of institutional discordant test pairs analysis
and baseline unit compliance (Figures 1 and 2) were presented
(in interrupted time sequence) to prospective peer leaders to
facilitate their recruitment. Peer leader volunteers then used the
baseline data and subsequent alterations in practice patterns to
motivate peers, using figural dashboards. The dashboard for-
mat illustrated in Figure 2 was adapted from previously pub-
lished methods31 and was amenable to institutional, service, or
peer-to-peer representation, depending on the judgment of the
service peer leader.
* In these 43 paents: 
• 0/43 discharged from emergency room 
• 37/43 admied 
• 5/43 observaon admissions 
• 1/43 died (not from MI), admission status not classified 
• 0/43 acute myocardial infarcons in 6-month follow-up 
• 1/43 negave stress test 
• 1/43 negave cardiac catheterizaon 
CK or MBI elevated CK and MBI 
normal 
Total 
cTnI elevated 1,001 1,708 2,709
cTnI normal 60 
(in 43 paents)*
4,725 4,785
Total 1,061 6,433 7,494
11,178 orders for “rule out 
MI” in 3,054 paents 
(baseline quarter)
8,716 (78%) non-compliant 
orders in 2,810 (92%) paents 
2, 462 (22%) guide-line compliant 
(cTnI only) orders in 990 (32%) 
paents
1,220 (14%) non-compliant orders 
cannot be evaluated (cTnI and 
CKMB not in same set)
7,496 (86%) non-compliant 
orders with sufficient data for 
value assessment
Figure 1. Decision tree and truth table for evaluating CKMB/MB
Index (MBI) performance that was used for to convince clinicians
to change their ordering patterns for the “rule-out myocardial
infarction” diagnosis. CKMB indicates creatine kinase M and B
isoenzyme.
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Peer leaders from EM, followed by Cardiology, and then
nonacademic hospitalists (who do not supervise residents)
sequentially introduced a service-level review of guidelines,
the format for dashboard feedback, baseline data for institu-
tional, and service-level experience. The feasible goal was con-
sistently presented as <100% compliance, acknowledging
clinical discretion to order CKMB if needed. Emergency Med-
icine created a goal of 75% guideline compliance. Subsequent
intervention groups including external hospitals targeted 75%
to 80% compliance.
Cost Calculations
We searched for simplified, reproducible models recom-
mended for cost reporting29,32,33 and emphasized to colleagues
that the approach favors transparency and replication rather
than economic sophistication. The formula was: (2012 Medi-
care reimbursement value)  (number of nonguideline orders)
 (% reduction goal) ¼ modeled cost opportunity. Year 2012,
Medicare reimbursements were US$16.25 for CKMB and
US$9.17 for CK. For purposes of tabular transparency, we
assumed 1:1 correspondence of these tests in the MI setting,
although CKMB tests were actually more common than CK
tests (61:39 in the modeled quarter). Reimbursement represents
one way to evaluate costs; a minimizing and equally transpar-
ent alternative substituted advertised disposable reagent cost
for the Medicare cost. This alternative also addressed the
ongoing transition in laboratory reimbursement, from an
income to a cost center. After intervention, outcomes were
revised to the achieved change in costs, using the actual
decrease in testing.
External Facilities
The intervention and supporting data including the internal
experience were presented in sequence (Figure 3) at 2 smaller,
rural hospitals, located >100 miles from the academic hospital.
Participating facilities belonged to a larger hospital system, in
which facility leaders retained independence over clinical pro-
tocols including quality improvement decisions. Academic
facility support to external peer leaders was limited to assis-
tance with altering electronic order sets, provision of the initial
presentation with the initial analysis of the performance of test
discordant data, and to access to dashboard feedback for use by
the peer leader during the intervention. External peer leader
characteristics and tasks differed from the academic site in
these ways: they were in private practice, they communicated
across disciplines with all clinical staff, and their intervention
began with the more interruptive (but still soft) “stop” requiring
a separate catalog order of CKMB and CK. All phases of the
external interventions (education, alterations to CPOE, and
peer feedback supported by dashboard reports) were imple-
mented simultaneously at external facilities, but the 2 external














































































































































































WVU IM resident joins
hospitalists
Planning
Figure 2. Percent compliance with guidelines for ordering cardiac markers compared to intervention milestones within services at academic
hospital looking at 3 different large specialty groups (Emergency Medicine, Cardiology, and Nonacademic hospitalists; ie, no residents rotate
with these individuals). Dates of interventions are color coded with Electronic medical record (EMR) interventions shown as black.
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Internal and External Validity
National data for R/O MI chest pain testing provided external
documentation of the change in test order intensity compared to
peer tertiary care University Health Consortium (UHC) mem-
ber organizations. Each UHC facility receives its own perfor-
mance compared to national norms for all similar facilities, but
not the performance of any other facility. University Health
Consortium membership can vary over time; quartile represen-
tations are therefore more useful than numerical place. A rep-
resentation of these data is in Table 1. Lower rank numbers
represent more parsimonious use of CKMB order sets. We also
investigated the relationship between order sets (which could
include orders for 1 to 3 tests) and total number of individual
tests, in order to provide internal validity. This activity would
have detected any internal trends related to changes in patient
visits or case mix, had they existed.
Results
Figure 1 shows that a minority of 11 178 last baseline quarter
order sets were guideline compliant at the academic facility,
with no consistent preintervention time trends in compliance.
Most (78%) noncompliant order sets contained the minimum
laboratory data (simultaneous CKMB and cTnI) needed to
evaluate their contribution to case-finding sensitivity. Of these,
60 order sets (<1%) featured the CKMBþ/cTnI () test dis-
cordance which might theoretically have added case-finding
sensitivity. Record review for the 60 discordant pairs in 43
affected patients revealed no MIs at the time or in the subse-
quent 6 months (0 positive predictive value). None of the 43
patients with the test discordant pattern were discharged, 37
were fully admitted, 5 were “observed” for an extended period,
and 1 died of noncardiac comorbidities, leaving 42 preventable
admissions in 43 affected patients. In addition, one of the 42
surviving patients received a subsequent cardiac catheteriza-
tion, and 1 received a nuclear stress test, with no significant
Table 1. UHC Data Comparing WVU Cardiac Markers Usage per
Adjusted Discharge to UHC Peer Institutions.*
Year and Quarter WVU Metric Mean Metric WVU Rank
2012 Q4 26.35 14.6 56 of 66
2013 Q1 14.34 14.8 33 of 65
2013 Q2 8.24 13.5 26 of 57
2013 Q3 4.36 12.29 22 of 62
2013 Q4 3.74 11.49 22 of 65
2014 Q1 3.95 10.65 17 of 51
2014 Q2 1.94 11.43 19 of 67
2014 Q3 1.04 11.49 18 of 71
2014 Q4 0.52 9.95 9 of 69
2015 Q1 0.48 9.36 11 of 69
Abbreviation: University Health Consortium.
* University Health Consortium data for cardiac marker utilization per adjusted
discharge showing our academic facility versus national peer institutions. Ini-























































































































































































1st Intervenon at WVUH
Intervenon at JMC Intervenon at BMC
Figure 3. Percent compliance with guidelines at 3 institutions. The interventions were performed sequentially in the 3 different institutions, first
at West Virginia University Hospitals, then Jefferson Medical Center (a Critical Access Hospital), and finally at Berkeley Medical Center and
analyzed as an interrupted time series analysis.
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disease detected. Other than the positive CKMB or MBI, rea-
sons for not discharging patients with the discordant pattern
were not revealed by record review, including absence of sug-
gestive EKG changes. Clinical colleagues interpreted decision
tree data to provide precise evidence for absence of clinical
benefit, with imprecise yet strongly suggestive evidence of
increased risk for unneeded admission and preventable costs
in the population, as well as possibly unjustified invasive
testing.
Real-world interventions are complicated, and our inter-
rupted time series internal intervention reflects some of these
realities. Most clearly seen for the initial intervention service
(EM, Figure 2), internal groups experienced some improve-
ments in guideline compliance during planning. However, pre-
intervention improvements were not sustained. In addition,
modest examples of cross-service contamination were detected
(Figure 2) at the academic facility. A rotating EM resident
transiently influenced guideline performance of the Cardiology
service about 4 weeks before the introduction of academic
detailing. The Cardiology peer leader detected the contaminat-
ing influence and highlighted it during introductory sessions to
motivate change (“We can’t let EM outperform cardiology”).
The nonacademic hospitalist service hired a former resident
who had participated in an earlier phase of the intervention
approximately 1 month before their intervention, creating a
preintervention change limited to 1 clinician.
System-wide “unchecking” of CK and CKMB tests
appeared less effective than the subsequent, relatively more
disruptive requirement for a separate order to trigger redundant
tests. However, the CMIO confirmed that many clinicians then
developed customized electronic “workarounds” facilitating
ongoing redundant orders. Sustained service-wide achievement
of increasing guideline compliance was achieved sequentially
in 3 services only after the initiation of peer leader academic
detailing, compared to either previous within-group perfor-
mance or to group(s) that had not yet undergone intervention
(P < .001). This statistical result was robust to using GLIMMs
and testing overall within-group differences, each P < .001.
External hospitals remained at baseline during the academic
hospital intervention (Figure 3) and then sequentially exceeded
goals (P < .001 for either within- or between-facility compar-
isons) following introduction of the time-compressed interven-
tion). Postintervention compliance gains were sustained, with
>95% compliance at the academic site and 85% compliance
at external hospitals. Slight contamination across neighboring
counties may have transiently influenced the second external
facility (Figure 3). Known and potential episodes of contam-
ination did not alter statistical paradigms at either the academic
or external facilities.
Table 1 (UHC data) documents a case mix–adjusted
national trend toward less CK and CKMB testing at academic
institutions and further indicates that redundant testing never-
theless persisted nationally during and after our interventions.
The change reported here clearly surpassed external trends with
improvement of our academic center from the fourth to the first
quartile. The most parsimonious UHC performers are believed
to have removed CKMB testing entirely from their laboratory
catalog, a step that our clinicians did not want to take. The
decline in the total number of tests is not accompanied by a
change in total order sets (Figure 4), so the improvement is not
a secular trend artifact of “diagnostic intensity.”
The achieved reduction in total tests, from 68 131 total
summed CKMB and CK tests in 15 months during 2011 to
2012 to 5627 such tests during 15 months in 2014 to 2015,
provides an annualized difference-modeled Medicare savings
as follows: > US$635 000 (in annualized 2011) in perpetuity
for just the index hospital and >US$138 000 annually for the
reagent model. This potentially rational approach may under-
estimate savings because our transparent cost model assumes a
1:1 correspondence of CKMB and CK tests, whereas the more
expensive CKMB test is actually more common. In addition,
the model underestimates postintervention increases in the
numbers of patients evaluated for R/O MI, associated with
ongoing maintained or even decreased per capita redundant
tests. However, it overestimates reagent savings because pub-
lished costs are higher than negotiated purchase costs. Further-
more, annualized and in-perpetuity approaches assume that the
unneeded tests would never be addressed but for this interven-
tion. We therefore present actual detailed modeled savings data
during the intervention (Table 2), so interested readers can
reach their own conclusions about savings during and after
intervention. Preventable hospitalization costs, arguably the
socially important costs implied by our data, were not modeled,
requested, nor feasible with resources available.
Clinicians appeared to accept that redundant testing was
very likely associated with preventable hospitalization,
although presenters stipulated that some CKMBþ/cTnI ()
patients might have been admitted anyway. Questions from
































Total monthly order sets (containing one or more test orders)
Total number of tests
Figure 4. Cardiac markers per month by order sets and tests. Note
that the number of tests dropped dramatically while the order sets
(containing 1 to 3 orders) remained the same, showing how clinicians
adopted the guideline of 1 test (ie, cardiac troponin I [cTnI]) over time,
thus reducing the number of tests performed.
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legal) concerns, temporal regimens for initiating the second
cTnI test in a series, methods of peer feedback, and time stres-
ses imposed by CPOE changes. A concern at rural sites,
whether the absence of CKMB testing would affect transfers
to regional cardiologists at neighboring tertiary care facilities
still doing CKMB testing, did not materialize as an operational
problem. External site partners were offered the opportunity to
recapitulate the truth table process or cost models from their
own data but expressed satisfaction with the modeled data from
the initial academic site.
Discussion
We propose these hypotheses concerning the critical role of
clinical laboratory data and teams that include pathologists in
quality improvement interventions. First, pathologists have an
essential role in providing decision support, such as identify-
ing, quantifying, and communicating low-value activities. Sec-
ond, when quality improvement opportunities are detected,
there are circumstances in which modeled case-finding sensi-
tivity data can address reasonable clinician concerns about
patient safety including belief that “our patients are different,”
a common concern in rural areas with poor transportation, low
income, and variable access to health care. The same data also
overcome inertia associated with unspoken concerns that stem
from normal human reluctance to change, including commis-
sion and status quo biases. We believe our experience illus-
trates that local laboratory data can tell a compelling story to
motivate collaborative change.
Third, we have added additional detail to the general knowl-
edge that multimodal interventions outperform changes to
CPOE alone. We assumed that removal of a low-value order
set was necessary to achieve change. Our subsequent findings
reinforce knowledge that CPOE changes need to be sufficiently
disruptive to capture attention but alone may still be insuffi-
cient, underperforming a combination of CPOE and peer lead-
ership supported by dashboard feedback. This is consistent
with existing behavioral7,8,13 and systems25-28 theory favoring
multimodal interventions. Pathology laboratory data are crucial
for providing the feedback about what kind of CPOE interven-
tion is sufficient. Expressed concerns about added time for soft
stops in CPOE fade when the barrier is to a test that clinicians
come to recognize as generally unhelpful.
Fourth, we provide data that interventions started in tertiary
care settings can be translated by private practice peer leaders
in rural hospitals, including a critical access facility. The more
rapid rate of guideline compliance at the external hospitals was
certainly assisted by the deliberate time compression of inter-
vention elements that had been independently tested at the
academic center. That may not be the whole story. Staff cohe-
sion and peer leader influence may also be greater at smaller
facilities. This finding begins to address a research need iden-
tified by Larochelle and colleagues, who provided an earlier
description of eliminating redundant MI orders and called for
demonstrations of external translation to additional facilities.22
We have begun that process.
Figure 1, depicting diagnostic futility and a near certain
probability of additional risk related to unneeded hospitaliza-
tion and procedures, may represent a figural template for the
kinds of motivation for change that pathologists can provide.
We should be clear that our finding, that the CKMB test fails to
add value to troponin testing, is anticipated by other work.34 It












Preintervention, July 2011-September 2012
(15 months)
64 341 132 472 68 131 US$865 945 US$376 764
During intervention, September 2012-December
2013 (15 months)
58 745 87 820 29 075 US$369 543 US$160 785
Postintervention, January 2014-March 2015
(15 months)
51 887 57 514 5627 US$71 519 US$31 117
Total tests reduced Total Medicare savings Total reagent savings
Imputed savings over the entire intervention# 101 560 US$1 290 828 US$561 627
Annual savings based on the last postintervention
period{
50 003 US$635 541 US$138 259
Abbreviations: CK, creatine kinase; CKMB, creatine kinase m and b isoenzyme; cTnI, cardiac troponin I.
*Savings are based on laboratory costs only; we did not estimate savings based on admitting fewer patients or on doing fewer procedures.
yA model of laboratory cost savings from reduction of redundant cardiac markers, looking at the unneeded tests and savings using 2012 Medicare reimbursement
rates and advertised reagent costs.
zFor cardiac markers, order sets equal tests performed on a 1:1 basis if only a cTnI was ordered. The difference between total tests and total order sets was
therefore estimated to be redundant tests.
§Medicare costs were estimated to the published per-test reimbursement (an order set containing a redundant CK and CKMB received the published 2011
Medicare reimbursement of US$25.42, and we estimated equal numbers of CK and CKMBs for cost purposes).
‹Savings were estimated to include only the published billing or per-test reagent costs (does not include labor, equipment depreciation, and assigned indirect costs
of performing these tests).
#Estimated savings ¼ preintervention modeled costs and postintervention modeled costs.
{Annual savings were calculated using the differences of redundant tests between the preintervention and postintervention periods, corrected to an annual rate.
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is nevertheless responsive to the near universal concern about
guidelines that “our patients are different” at a facility or within
a region. The laboratory can lead collaborations that seek to
measure if that concern is realistic and the effort to show
whether a nonrecommended test provides some benefit can
detect the still more compelling finding that a test is doing
harm. Future work might formally investigate whether peer
leadership for targeted laboratory orders can also reduce some
of the well-known variability in admissions, including from
EDs for chest pain.35
Fifth, we were not surprised to confirm that clinicians and
administrators routinely expressed interest to see modeled cost
implications. In this case, a simplified economic model indi-
cates a >US$635 000 annual savings in 2012, with no addi-
tional inputs required for ongoing savings once the intervention
was complete. These savings were similar to the savings found
by Zhang et al24 for billing costs, and our calculated reagent
savings were greater than the reagent savings calculated for an
ED intervention by Le et al23 likely because of the use of
transparently published reagent costs, compared to actual but
invisibly discounted reagent costs. More fundamentally, we
were not surprised to learn that clinicians responded to the
cost data with interest but were not particularly impressed by
savings alone. Instead, the savings in the setting of improved
care with fewer errors were compelling and are more repre-
sentative of the critical role of pathologists and interdisciplin-
ary colleagues in assessing the performance and value
laboratory tests. In this sense, all cost models greatly under-
estimate the actual societal savings. An advantage of simpli-
fied cost models is their transparency to participants from
many kinds of backgrounds, removing the uncertainty inher-
ent in concealment or ignoring of cost implications, and
avoiding the time and investment associated with more rig-
orous economic models. Clinicians readily understood and
accepted the limitations of simplified models and saw no
need to improve on them.
Nevertheless, fundamental concerns about the best ways to
intervene remain. These are largely unrelated to the simplifica-
tions in our cost model but do relate to costs and benefits. More
expensive laboratory orders may have a different dynamic,
particularly when they are “sendouts.” When tests are more
expensive and become significant institutional costs or signif-
icant institutional income depending on the setting, the impor-
tance of the evaluative role of pathologists increases.
Pathologists have a key role in making sure that both costs and
the quality of outcomes are considered; laboratory performance
data are the best response to the pressures that surround com-
peting views of costs.
Our approach and findings feature strengths that may assist
several research and practical implementation needs. The US
National Academy of Sciences, Engineering, and Medicine has
identified interdisciplinary participation of laboratory clini-
cians with direct patient care clinicians as important to leader-
ship for quality improvement.36 In addition, trainees at several
career stages and from several specialties were able to make
contributions to a real-world intervention, suggesting that the
approach may have positive implications for career develop-
ment. External validity was demonstrated relative to national
secular trends at peer institutions (Table 1), and internal valid-
ity testing shows that the change is independent of diagnostic
intensity (Figure 4). The “decision tree” data (Figure 1) is a
strength that can assist to recruit intervention partners, includ-
ing partners in private practice. In this case, it responded to
clinician concerns and also suggested previously overlooked
harms of baseline low-value tests. We hypothesize that this
approach is scalable to other facilities and clinical contexts.
Our approach also features some common limitations of
intervention research. We are concerned that the intervention
sounds complicated. The intervention is simple; any appear-
ance of complexity is in the effort to transparently show con-
vincing data of what was done and what resulted, an important
requirement of quality improvement and time sequential study
designs. Although sequential internal and then external suc-
cesses appear promising, time sequential intervention designs
are imperfect and require detailed presentation, as they substi-
tute for randomized assignments in the setting of clinical qual-
ity interventions, providing inferences instead of proofs.32,33
Despite the detail inherent in peer descriptions of methods and
data, our data clearly show that facilities can implement this
change rapidly, with the time it takes to make CPOE changes as
the most important temporal barrier.
A limitation related to scalability is that external translation
of the intervention was supported by shared data in an acces-
sible warehouse. External intervention partners often lack a
shared data resource, suggesting a data gap pertaining to future
scalability until medical records better accommodate data
exchanges while protecting patient privacy. To address this
gap, we have planned additional demonstrations with hospitals
that do not share data, including hospitals of varying sizes and
hospitals that normally compete for market share. Another
research gap for scalability is how well decision tree and truth
table data will influence clinical behavior when the findings are
less clear than the perfect futility we demonstrated for redun-
dant CKMB testing. Our data do not fully address whether
more complex analyses such as receiver-operator curves can
also be motivating when needed. Patients with low-risk chest
pain presentations experience low rates of adverse cardiac
events.37 Other clinical decisions may have more nuanced
comparisons between risks and benefits of admission compared
to low-risk chest pain. Nevertheless, our findings strongly sup-
port the case that data-driven approaches to selection of appro-
priate laboratory orders will become increasingly important in
many settings.38
A word about the progress of intervention research is also in
order. After we planned and implemented our intervention,
SQUIRE II updates39 and summarized Agency for Healthcare
Research and Quality (AHRQ) planning advice40 became
available for quality improvement interventions. We commend
these updated tools to colleagues’ planning quality improve-
ment interventions.
In summary, our experience leads to testable hypotheses
about the critical role of pathologists in providing data that can
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motivate change. We propose that clinical leadership and clinical
staff more willingly abandon low-value laboratory practice pat-
terns and improve care when specific local laboratory data reveal
that current practices are ineffective and/or that they may
increase patient risk. We have shown that an intervention tested
in an academic setting, when supported by relevant performance
data, can be reliably adapted and led by private practice peer
leader clinicians, including at small rural facilities. We have
presented a visual picture of the relative increments of several
kinds of CPOE and the subsequent addition of peer leadership,
confirming that soft stops cannot be too soft, CPOE alone is only
a partial answer, and peer leadership is needed to achieve change.
In addition, we provide a successful example of an identified
national need, data-driven collaboration between laboratory and
other clinical staff to improve quality.36 Leading authorities
understand that clinicians are a widely available yet underuti-
lized resource in quality improvement.8,13 Our approach, utiliz-
ing laboratory expertise and laboratory data to motivate clinical
behavioral change, may be investigated for utility in needed,
wider engagement of clinician energy and capability in quality
improvements that are responsive to public health needs.
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